Takeda Pharmaceutical Co Ltd ADR (TAK)vsViatris Inc (VTRS)
TAK
Takeda Pharmaceutical Co Ltd ADR
$17.82
-1.60%
HEALTHCARE · Cap: $57.56B
VTRS
Viatris Inc
$13.20
-2.22%
HEALTHCARE · Cap: $15.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 31121% more annual revenue ($4.46T vs $14.30B). TAK leads profitability with a 2.5% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.07. TAK earns a higher WallStSmart Score of 60/100 (C).
TAK
Buy60
out of 100
Grade: C
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.5%
Fair Value
$10.30
Current Price
$17.82
$7.52 premium
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Every $100 of equity generates 150 in profit
Earnings expanding 330.2% YoY
Generating 317.5B in free cash flow
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
4.2% revenue growth
2.5% margin — thin
Premium valuation, high expectations priced in
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Return on Equity. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.07 suggests the stock is reasonably priced for its growth.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Profit Margin, P/E Ratio. A P/E of 82.8x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
TAK profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.80 — expect wider price swings.
VTRS is growing revenue faster at 5.0% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (60/100 vs 50/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?